Osimertinib
Osimertinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Lung Cancer、Breast Cancer、Non-Small Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
6 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Bristol-Myers Squibb
- AbbVie
- Pusan National University Hospital
- Tianjin Medical University Cancer Institute and Hospital
- Jonsson Comprehensive Cancer Center
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- National University Hospital, Singapore
- Samsung Medical Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
South Korea、中国、美国、Singapore、Israel、意大利、中国香港、澳大利亚、奥地利、比利时、加拿大、法国
正在招募患者的 Osimertinib 研究
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
II 期招募中South KoreaNCT07073365Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
II 期招募中中国NCT05686434Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
II 期招募中美国NCT07323641A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
II 期招募中中国NCT07622186Osimertinib for Advanced EGFR-positive NSCLC Patients
不适用招募中SingaporeNCT05037331Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
II 期招募中South KoreaNCT05528458TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
II 期招募中中国NCT05948813Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
II 期招募中IsraelNCT06206850A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
II 期招募中中国NCT07375316A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
不适用招募中IsraelNCT05033691Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
不适用招募中意大利NCT07363252Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
II 期招募中中国香港NCT07379476Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
I 期 / II 期招募中美国NCT04486833A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
II 期 / III 期招募中美国澳大利亚奥地利比利时NCT07155187Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
III 期招募中美国Argentina澳大利亚BrazilNCT07680790Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
II 期招募中加拿大NCT04335292Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
III 期招募中中国NCT05382728Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
II 期招募中中国台湾NCT05805631Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
IV 期招募中中国NCT07279935Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
不适用招募中美国NCT07028489A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
III 期招募中中国NCT06829459A Study of DB-1310 in Advanced/Metastatic Solid Tumors
I 期 / II 期招募中美国中国NCT05785741Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
III 期招募中美国澳大利亚加拿大中国NCT07185997A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
II 期招募中中国NCT07669779
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。